China's Hepa Thera announced on 2 July that its hepatitis B siRNA therapy HT-101 was granted breakthrough therapy designation (BTD) for chronic hepatitis B virus (HBV) infection. HT-101 targets HBV surface antigen (HBsAg) to suppress viral replication and reduce antigen levels. Preliminary data presented last year showed a 3.29 log reduction in HBsAg by week 16 in high-dose groups.

As a leading HBV innovator, Hepa Thera joins domestic peers like Argo Biopharmaceutical (siRNA) and GCE Healthcare (therapeutic vaccine) in advancing HBV treatments through China's BTD pathway. HT-101 is the company's lead candidate in its liver disease pipeline. China's HBV drug development now leads globally across multiple modalities, including AusperBio's AHB-137 antisense oligonucleotide (ASO) therapy, which has achieved unprecedented HBsAg clearance data.

Source:
https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247527862&idx=1&sn=2b1a32a9969b111533caa0772fc6333f